| Project/Area Number |
10557095
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | National Cardiovascular Center Research Institute |
|---|
Principal Investigator |
KATO Hisao National Cardiovascular Center Research Institute, Director of Division of Etiology and Pathogenesis, 病因部, 部長 (80029959)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOHNO Isao Iatron laboratories Inc., 係長
KAMIKUBO Yu-ichi The Chemo-Sera-Therapeutics Institute, staff, 室長
KAWAGUCHI Akito National Cardiovascular Center Research Institute, staff, 病因部, 室員 (70214608)
WADA Hideo Mie University School of Medicine, Instructor, 医学部, 助手 (40158704)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥4,500,000 (Direct Cost: ¥4,500,000)
Fiscal Year 1999: ¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1998: ¥2,400,000 (Direct Cost: ¥2,400,000)
|
|---|
| Keywords | Anticoagulant / endothelial cell / diagnosis / cardiovascular disease / TFPI / beta-2-glycoprotein I / monoclonal antibody / DIC / anti-phospholipid antibody syndrome / 動脈硬化 / 測定法 |
|---|
| Research Abstract |
The anticoagulant properties of vascular endothelial cells are regulated by various mechanisms. In this study, we focused on two proteins, TFPI and beta2-glycoprotein I, which are supposed to be closely associated with the anicoagulant property of endothelial cells. TFPI is a protease inhibitor with the ability to inhibit the initial reactions of the blood coagulation cascade. Beta-glycoprotein I has the ability to bind with various negatively-charged substances and plays major role in anti-phospholipid syndrome. Our purpose of this study is the development of the novel methods for these two proteins and the clinical application of these methods.
We prepared a specific monoclonal antibody for a complex of TFPI-Xa and established a method to measure the complex in plasma. We found that the level of the complex is significantly higher in DIC patients than in normal control.
We also prepared a specific monoclonal antibody for a nicked form of beta2-glycoprotein I and established a method to measure the nicked form in plasma. We found that the level of the nicked form is significantly higher in the patients with DIC and anti-cardiolipin antibody.
|
